Brain Imaging and Whole Blood Targeted Transcriptomic Analyses to Characterize Cerebral Infarctions in Children With Tuberculous Meningitis - Scorecard - MDSpire
Advertisement
Brain Imaging and Whole Blood Targeted Transcriptomic Analyses to Characterize Cerebral Infarctions in Children With Tuberculous Meningitis
Clinical Scorecard: Utilizing Brain Imaging and Targeted Transcriptomic Analysis of Whole Blood to Investigate Cerebral Infarctions in Pediatric Patients with Tuberculous Meningitis
At a Glance
Category
Detail
Condition
Cerebral infarctions in pediatric tuberculous meningitis (TBM)
Key Mechanisms
Inflammation-mediated vasculitis causing ischemia and infarction; involvement of matrix metalloproteinases, proinflammatory cytokines, and growth factors disrupting blood-brain barrier
Target Population
Children aged 29 days to 18 years diagnosed with tuberculous meningitis
Care Setting
Hospital-based clinical and imaging evaluation with specialized neuroradiology and transcriptomic analysis
Key Highlights
63% of children with TBM had cerebral infarctions, commonly acute, multiple, and bilateral, affecting cerebral hemispheres, basal ganglia, and thalamus.
Children with infarctions showed higher cerebrospinal fluid protein, lower CSF glucose, and elevated systemic MMP-8 expression.
Adjunctive corticosteroids reduce mortality but have limited effect on infarct incidence; high-dose aspirin is under investigation for infarct reduction.
Guideline-Based Recommendations
Diagnosis
Use baseline brain MRI within ±7 days of enrollment to detect cerebral infarctions, including diffusion-weighted imaging for acute infarcts.
Classify TBM diagnosis as definite, probable, or possible using published uniform research case definitions.
Assess disease severity using refined British Medical Research Council grading.
Management
Administer adjunctive anti-inflammatory corticosteroids to reduce mortality in TBM.
Consider adjunctive high-dose aspirin for potential infarct reduction pending results of phase 3 trials.
Employ short intensified antituberculosis therapy as per ongoing clinical trial protocols.
Monitoring & Follow-up
Perform serial brain MRI scans to monitor infarct progression and complications such as hydrocephalus and meningeal enhancement.
Monitor cerebrospinal fluid parameters including protein and glucose levels.
Evaluate systemic inflammatory markers including MMP-8 expression via targeted transcriptomic analysis.
Risks
High risk of death or poor neurodevelopmental outcomes associated with cerebral infarctions in TBM.
Excessive inflammation can disrupt blood-brain barrier leading to neuronal injury and long-term deficits.
Patient & Prescribing Data
Children with tuberculous meningitis enrolled in clinical trial evaluating intensified antituberculosis therapy and adjunctive aspirin
Adjunctive corticosteroids reduce mortality but do not significantly reduce infarct incidence; high-dose aspirin is under investigation for infarct prevention.
Clinical Best Practices
Perform early and standardized brain MRI imaging including diffusion-weighted sequences to detect and characterize cerebral infarctions.
Use targeted whole blood transcriptomic analysis to assess systemic inflammatory mediators such as MMP-8, cytokines, and growth factors.
Apply multidisciplinary consensus reading of imaging by experienced neuroradiologists blinded to clinical data.
Incorporate clinical severity grading and CSF biochemical analysis to correlate with imaging and transcriptomic findings.
Consider adjunctive anti-inflammatory therapies while awaiting further evidence on aspirin efficacy.
by Julie Huynh, Pieter M Pretorius, Wajanat Jan, Carolina Kachramanoglou, Nhat Hoang Thanh Le, Van La Ngoc, Hai Thanh Hoang, Ny Thi Hong Tran, Tram Ngoc Pham, Thu Anh Dang Do, Dung Thi Mong Vu, Trinh Thi Bich Tram, Do Dinh Vinh, Tung Huu Trinh, Nguyen Dinh Qui, Minh Ha Thi Dang, Elena Frangou, Sierra Santana, Caitlin Muller, Suzanne T Anderson, Diana M Gibb, Nhung Thi Hong Nguyen, Nguyen Thuy Thuong Thuong, Guy Thwaites, on behalf of the SURE Trial Team
